

Bladder Preservation Program

Presented by:

Paul Crispen, MD
Associate Professor, Urology
University of Florida College of Medicine

Faculty Disclosure:

Dr. Crispen has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose.

CME Advisory Committee Disclosure

Conflict of interest information for the CME Advisory Committee members can be found on the following website:
<https://cme.ufl.edu/disclosure/>.

Release Date: Feb 1, 2020

Expiration Date: January 31, 2022

Target Audience:

Urologists, Female Pelvic Medicine and Reconstructive Surgery Specialists

Learning Objectives:

As a result of participation in this activity, participants should be able to:

1. Understand the current indications for radical cystectomy when treating bladder cancer.
2. Define the BCG refractory disease and treatment options outside of radical cystectomy for BCG refractory disease.
3. List patient and tumor characteristics that are associated with improved outcomes with Trimodal therapy for muscle invasive bladder cancer.
4. Describe 3 methods being evaluated to improve bladder preservation therapy in patients with BCG refractory disease and muscle invasive disease.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact Info: If you have any questions please feel free to contact Brittany Purcell at 352.265.0373 or at bpur0003@shands.ufl.edu

[Click here to listen to the lecture!](#)